Epidiolex Counterpart Debuts In Brazil's Cannabis Market As Its Maker Eyes TSX IPO
Portfolio Pulse from Javier Hasse
Pharmaceutical company Verdemed has received five approvals from the Brazilian Health Regulatory Agency, making it the leader in authorized cannabis-based medications in Brazil. The company now offers products such as Canabidiol Verdemed, a counterpart to Jazz Pharmaceuticals' Epidiolex. Verdemed plans to double its product sales by the end of 2024 and is set to channel investments into research and development. The company has also initiated a new investment round to raise $3 million and plans to undertake an IPO on the Toronto Stock Exchange.
August 23, 2023 | 7:57 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Verdemed now offers a product that is a counterpart to Jazz Pharmaceuticals' Epidiolex. This could potentially impact Jazz Pharmaceuticals' market share in the cannabis-based medication sector.
The introduction of a product that is a counterpart to Jazz Pharmaceuticals' Epidiolex by Verdemed could potentially lead to a decrease in Jazz Pharmaceuticals' market share in the cannabis-based medication sector. This is because Verdemed's product could attract customers who would have otherwise chosen Jazz Pharmaceuticals' Epidiolex.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50